Business context and reporting period
Bioceres Crop Solutions Corp. filed an audited Form 20-F for the fiscal year ended June 30, 2023, prepared under IFRS in U.S. dollars. This is an annual report, not a 2022 Q4 filing; standalone quarterly results are not provided in the supplied filing text. The company develops and sells agricultural biologicals, crop protection and nutrition products, seeds, and biotechnology traits, including licensed HB4 drought-tolerance technology.
FY2023 includes Pro Farm, acquired July 12, 2022; FY2022 does not, limiting direct comparability. The company also received a $50 million upfront payment under its 10-year Syngenta agreement.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue from customer contracts | $419.4 million | $328.5 million |
| Total revenue measure cited in MD&A | $420.1 million | $334.8 million |
| Gross profit | $184.6 million | $126.4 million |
| Operating profit | $54.2 million | $39.9 million |
| Profit (loss) for the year | $20.2 million | $(3.9) million |
| Adjusted EBITDA (non-IFRS) | $81.2 million | $51.5 million |
| Operating cash flow | $2.6 million | $(17.5) million |
| Investing cash flow | $(25.7) million | $2.9 million |
| Financing cash flow | $33.0 million | $14.8 million |
| Cash and cash equivalents at year-end | $48.1 million | $33.5 million |
Gross margin was approximately 44% using gross profit divided by the MD&A total-revenue measure; operating margin was approximately 13%, and net margin approximately 5%. Segment margins reported in the audited segment note were 44% for seed and integrated products, 33% for crop protection, and 57% for crop nutrition. Adjusted EBITDA is management-defined and excludes, among other items, finance costs, taxes, depreciation and amortization, share-based compensation, and specified transaction items.
At June 30, 2023, total indebtedness was reported as $243.5 million, including $168.3 million of borrowings and $75.2 million of secured notes. About $107.6 million of borrowings was current; approximately 56% of total indebtedness was described as long-term. Cash plus current other financial assets was about $60.3 million. Current assets were $397.1 million and current liabilities $298.7 million.
Material changes versus the prior comparable year
- Revenue increased 25% on the MD&A measure, while customer-contract revenue increased about 28%. Pro Farm contributed $42.3 million of revenue after acquisition, including $14.1 million cited in the MD&A discussion.
- Crop nutrition grew most strongly, to $157.3 million from $109.1 million, driven by biostimulants, inoculants and micro-beaded fertilizer. Crop protection rose to $205.8 million from $174.4 million, but was nearly flat excluding Pro Farm, amid weather-related pressure and elevated channel inventories. Seed and integrated products increased to about $56.7 million from $51.3 million.
- Gross profit increased by about $57.9 million. Management cited $34.1 million of positive results related to Syngenta and $24.9 million of gross-profit contribution from Pro Farm. Seed and integrated products gross-profit contribution fell 13%, which management attributed to product mix.
- R&D expense rose to $15.3 million from $6.9 million, and selling, general and administrative expense rose to $113.0 million from $77.5 million, substantially reflecting Pro Farm and increased operating costs.
- Net financial costs increased to $35.1 million from $25.8 million. The company moved its main Argentine subsidiaries’ functional currency from pesos to U.S. dollars effective July 1, 2022; management says significant inflation adjustments consequently no longer affected FY2023 statements.
- Total assets increased to $818.1 million from $518.2 million, including goodwill of $112.2 million and intangible assets of $173.8 million, reflecting mainly the Pro Farm acquisition and purchase accounting.
Outlook, commentary, risks and unusual items
- Outlook: The filing gives no quantified revenue or earnings guidance. Management’s stated priorities include commercializing HB4 products, expanding international biological-product sales, scaling production, and pursuing partnerships and acquisitions. The company says existing cash, operating inflows and borrowing access should meet anticipated needs for the next 12 months, but notes that additional financing may be needed if resources prove insufficient.
- Commercial agreements: Syngenta became exclusive global distributor for specified Rizobacter biological seed-care products, subject to territory phasing and regulatory clearances. The agreement provides for $230 million in minimum profits to Bioceres over its life, with exclusivity remedies if rolling targets are missed. A portion of the $50 million upfront payment remained deferred at year-end: $32.9 million had been recognized and $17.1 million was deferred, principally pending access to later-phase territories.
- Liquidity and debt: Operating cash flow was modest despite positive earnings, as working capital consumed $83.8 million. The filing identifies $107.6 million of current borrowings and warns that cash generation or refinancing may be insufficient to meet debt obligations. The convertible notes due 2026 carry 5% cash interest plus 4% payment-in-kind interest and are convertible; conversion would dilute shareholders.
- Key risks: Argentina’s inflation, exchange controls, currency volatility, import-payment restrictions and mandatory export-proceeds repatriation may affect costs, cash transfers and debt service. Other material risks include seasonal and weather-driven demand, product-development and regulatory uncertainty, GM-crop acceptance, competition, acquisition integration, raw-material availability, and reliance on licensed HB4 technology and collaborators.
- Contingency: Litigation over historical Rizobacter share transfers remains subject to an injunction affecting shares held by the company; an unfavorable outcome could reduce its ownership. The filing also describes a potential $17.3 million contingent purchase price associated with the dispute. Certain dividends on affected shares are held in judicial escrow.
- Unusual and audit matters: The $50 million Syngenta upfront license payment materially affected revenue recognition. The auditor identified critical audit matters involving goodwill and intangible-asset impairment estimates, Pro Farm acquisition intangible valuation, and the functional-currency change. Management and the auditor reported effective internal control over financial reporting, but Pro Farm—representing 9% of assets and 10% of revenue—was excluded from their control assessment.
- Data caution: The filing’s MD&A contains inconsistent wording about FY2023 profit versus loss; the audited statements report profit of $20.2 million. It also gives differing seed-and-integrated-products revenue figures in different sections. Use the audited financial statements and segment note when confirming those figures.
Most important facts for investors to verify
- Reconcile the $420.1 million MD&A total-revenue measure to audited customer-contract revenue of $419.4 million and other biological-asset items; confirm which measure is used for comparisons.
- Review debt maturities, covenant headroom, refinancing plans and the sources available to cover the $107.6 million current borrowing balance and working-capital needs.
- Assess cash conversion: operating cash flow was $2.6 million despite $20.2 million of profit, with an $83.8 million working-capital outflow.
- Track Syngenta’s phased market rollout, regulatory clearances, recognition of deferred revenue, and progress toward the $230 million minimum-profit targets.
- Evaluate Pro Farm integration and the assumptions supporting goodwill and intangible carrying values, including the auditor’s critical audit matters.
- Monitor the Rizobacter injunction and related contingent consideration, as well as Argentine exchange-control and export-repatriation developments.
- Confirm HB4 regulatory approvals and commercialization progress, including the ability to earn royalties and expand beyond currently approved markets.